Comparative Pharmacology
Head-to-head clinical analysis: BRETHINE versus ISOETHARINE HYDROCHLORIDE S F.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRETHINE versus ISOETHARINE HYDROCHLORIDE S F.
BRETHINE vs ISOETHARINE HYDROCHLORIDE S/F
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist; stimulates adenylate cyclase, increasing intracellular cAMP, leading to relaxation of bronchial smooth muscle and inhibition of mast cell mediator release.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.
5 mg orally three times daily; may increase to 10 mg if needed; maximum 20 mg daily. Subcutaneous: 0.25 mg, may repeat once in 15-30 minutes (not to exceed 0.5 mg in 4 hours).
Inhalation: 1-2 inhalations of a 340 mcg/metered dose every 4 hours as needed. Nebulization: 500 mcg (0.5 mL of a 0.1% solution) every 4 hours as needed.
None Documented
None Documented
3-8 hours (terminal); shorter in children and smokers; prolonged in hepatic impairment
2-4 hours; clinical context: short half-life supports continuous or repeated dosing for acute bronchospasm.
Renal: 50-60% as unchanged drug and metabolites; biliary/fecal: 20-30%
Primarily renal excretion of unchanged drug and metabolites; 60-70% excreted in urine as unchanged drug and sulfate conjugates, with less than 10% eliminated in feces via biliary excretion.
Category C
Category C
Beta-2 Adrenergic Agonist
Beta-2 Adrenergic Agonist